Home Ingredients Apoaequorin Protein
CognitiveLongevity

Apoaequorin Protein

Evidence Level
Limited
2 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

Apoaequorin is a calcium-binding protein originally isolated from the bioluminescent jellyfish Aequorea victoria. It is the active ingredient in the commercial brand Prevagen, which has been marketed for memory support in older adults. The premise is that supplemental calcium-binding proteins might compensate for age-related decline in endogenous calcium-buffering proteins in the brain. However, the supporting evidence is limited and contested. In 2017 the US Federal Trade Commission and New York Attorney General sued Quincy Bioscience, Prevagen's maker, alleging that memory-improvement claims were unsupported by reliable scientific evidence. Litigation has continued for years, with mixed outcomes. Independent peer-reviewed research is sparse, and most published clinical data come from the manufacturer. Consumers should be aware of this context when evaluating the product.

Studied Dose Manufacturer trials have typically used 10 mg of apoaequorin per day; the commercial product Prevagen contains 10 mg per capsule.
Active Compound Apoaequorin, a 22 kDa calcium-binding protein with EF-hand motifs, structurally similar to calmodulin and other intracellular calcium buffers.

Benefits

Marketed for memory support

Apoaequorin is sold primarily as a supplement intended to support memory in older adults experiencing age-related mild forgetfulness. The hypothesized rationale is supplemental calcium-buffering, though independent evidence supporting these claims is limited and the topic remains subject to ongoing regulatory and legal scrutiny.

Supported by Trial 1, Trial 2

Calcium-binding protein supplementation

The product is positioned around the idea that providing an additional calcium-binding protein may help support intracellular calcium balance in neurons. Whether dietary apoaequorin survives digestion and reaches brain tissue intact remains a key open scientific question.

Supported by Trial 1

Studied for everyday cognition

Manufacturer-funded studies have examined effects on word recall and other cognitive performance measures in older adults. Results have been modest and inconsistent, and replication by independent research groups has been limited to date.

Supported by Trial 1

Generally well-tolerated short-term

In published trials of up to 90 days, apoaequorin has been reported to be generally well-tolerated, with side effect rates similar to placebo. Long-term safety data and effects in clinically diagnosed cognitive conditions have not been thoroughly evaluated.

Supported by Trial 1

Mechanism of action

1

Hypothesized calcium buffering

The proposed mechanism is that supplemental apoaequorin acts as an additional intracellular calcium-buffering protein, potentially compensating for age-related declines in endogenous calcium-binding proteins like calbindin in neurons. This mechanism is largely theoretical.

2

Protein digestion concerns

Independent analyses note that apoaequorin is a protein and would be expected to be broken down into amino acids and peptides by stomach acid and digestive enzymes, similar to dietary proteins. How intact protein could cross the gut and blood-brain barrier remains unclear.

3

Structural similarity to native proteins

Apoaequorin shares EF-hand calcium-binding motifs with mammalian proteins such as calmodulin and calbindin. Whether structural similarity alone translates to functional effects after oral consumption has not been established by independent research.

Clinical trials

1
Manufacturer-sponsored memory trial

90-day randomized placebo-controlled trial using 10 mg apoaequorin daily.

Older adults with self-reported age-related memory concerns.

The published manufacturer-funded study reported small improvements on certain cognitive tasks in subgroup analyses but did not demonstrate broad statistically significant benefit on primary outcomes. Independent replication has been limited, and the FTC has challenged the strength of the supporting evidence.

2
FTC regulatory context

Not a clinical trial, but relevant context: the FTC and NY Attorney General filed action against the manufacturer in 2017.

Regulatory review of marketing claims.

Regulators alleged that memory-related claims were not adequately supported by the available evidence. Subsequent litigation has had mixed procedural outcomes, but the case underscores the importance of viewing apoaequorin claims with appropriate skepticism.

Side effects and drug interactions

Common Potential side effects

Headache reported by a small number of users.
Dizziness in occasional cases.
Mild gastrointestinal upset.
Sleep disturbances in some users.
Generally low overall adverse event rate in short-term trials.

Important Drug interactions

No well-characterized drug interactions reported to date.
Limited interaction data due to sparse independent research.
Consult a healthcare provider if taking cognitive-related medications.
Caution advised when combined with other calcium-modulating supplements.

More Cognitive Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…

Explore Other Ingredients

Cognitive
Lion's Mane Mushroom
Lion's mane (Hericium erinaceus) is an edible medicinal mushroom prized for its potential…
Cognitive
Bacopa Monnieri
Bacopa monnieri (Brahmi) is a cornerstone herb in Ayurvedic medicine with over 3,000 years…
Cognitive
Phosphatidylserine
Phosphatidylserine (PS) is a phospholipid concentrated in neuronal cell membranes (10-20%…

Frequently asked questions about Apoaequorin Protein

What is apoaequorin used for?

Apoaequorin is a protein originally derived from a glowing jellyfish, marketed (notably in the product Prevagen) for memory and cognitive support in aging. It is claimed to support brain calcium regulation.

Does apoaequorin improve memory?

The memory claims are controversial: independent experts and regulators have questioned the supporting evidence, and as a protein, apoaequorin would be expected to be digested rather than reach the brain. Be skeptical of strong memory claims.

How much apoaequorin should I take?

Branded products provide a set daily amount (often around 10 mg); follow product labeling. Given the disputed evidence, keep expectations low.

Is apoaequorin safe?

It appears generally well tolerated in reported use. The main issue is effectiveness rather than safety; the marketing claims have faced legal and regulatory challenges. Check with a doctor about memory concerns, which warrant proper evaluation.

What is Apoaequorin Protein?

Apoaequorin is a calcium-binding protein originally isolated from the bioluminescent jellyfish Aequorea victoria. It is the active ingredient in the commercial brand Prevagen, which has been marketed for memory support in older adults.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Moran DL, Underwood MY, Gabourie TA, Lerner KC. Effects of a supplement containing apoaequorin on verbal learning in older adults in the community. Adv Mind Body Med. 2016;30(1):4-11..PubMedUsed to support: Madison Memory Study — 90-day RCT in 218 adults aged 40-91 with self-reported memory concerns. The primary endpoints did not reach statistical significance; reported 'improvements' came from post hoc subgroup analyses, a finding subsequently flagged by the FTC as not supporting Prevagen's memory-improvement marketing claims.
  2. Federal Trade Commission and State of New York. FTC, New York State Charge the Marketers of Prevagen With Making Deceptive Memory, Cognitive Improvement Claims (Press release and complaint, FTC v. Quincy Bioscience Holding Co., 17-cv-124, S.D.N.Y.). U.S. Federal Trade Commission. 2017;Civil complaint filed January 9, 2017; case ongoing through 2024 ruling..SourceUsed to support: Regulatory action documenting that the Madison Memory Study's primary endpoints failed to show statistically significant memory benefit and that oral apoaequorin is digested into amino acids/peptides like any dietary protein, making the marketed memory claims unsubstantiated.